Form 4: Guardant Health Director Ian T. Clark Reports Stock Transactions
SEC Form 4
Director Ian T. Clark reports transactions involving Guardant Health stock, including the vesting and disposal of restricted stock units and the grant of stock options.
Summary
- On June 12, 2024, Ian T. Clark, a director of Guardant Health, Inc., reported transactions involving the company's stock.
- Clark disposed of 6,776 shares of common stock.
- Clark also acquired 6,776 shares of common stock through the vesting of restricted stock units.
- Additionally, Clark was granted 10,703 stock options with an exercise price of $31.84, vesting fully on June 12, 2024, or the date of the next annual stockholders meeting.
- Clark was also granted 8,088 restricted stock units vesting fully on June 12, 2024, or the date of the next annual stockholders meeting.
- Following these transactions, Clark directly owns 10,703 stock options and 8,088 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and expected as part of executive compensation. The disposal of shares is likely related to tax obligations from vesting.
Positives
- The granting of stock options and restricted stock units to a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Negatives
- The disposal of 6,776 shares could be interpreted negatively, although it is likely related to the vesting of restricted stock units and associated tax obligations.
Risks
- Significant stock transactions by insiders could create uncertainty among investors if not properly understood.
Industry Context
Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's current valuation and future prospects. Form 4 filings are a standard part of regulatory compliance for corporate insiders.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are common forms of executive compensation in the biotechnology and healthcare industries.
- Companies like Illumina, Roche, and Thermo Fisher Scientific also utilize similar equity-based compensation plans to incentivize their executives and align their interests with shareholders.
- The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and stage of development.
Stakeholder Impact
- The transactions have a minor impact on shareholders, primarily through potential dilution from the exercise of stock options in the future.
- The granting of equity-based compensation aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/14/2023 | Original grant date of some restricted stock units, vesting one year after this date or the date of the next annual stockholders meeting, whichever is earlier. |
| 06/12/2024 | Date of the reported transactions, including disposal of shares, vesting of restricted stock units, and grant of stock options and restricted stock units. |
| 06/12/2024 | Grant date of stock options and some restricted stock units, vesting one year after this date or the date of the next annual stockholders meeting, whichever is earlier. |
| 06/12/2034 | Expiration date of the granted stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.